{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T17:26:31Z","timestamp":1791134791155,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gene"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.gene.2015.01.010","type":"journal-article","created":{"date-parts":[[2015,1,10]],"date-time":"2015-01-10T01:48:36Z","timestamp":1420854516000},"page":"31-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy"],"prefix":"10.1016","volume":"559","author":[{"given":"Xiangxiang","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijian","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gene.2015.01.010_bb0005","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gene.2015.01.010_bb0010","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1200\/JCO.2009.24.4491","article-title":"Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies","volume":"28","author":"Ciccolini","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gene.2015.01.010_bb0015","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.gene.2015.01.010_bb0020","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/FPC.0b013e32834e3572","article-title":"The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma","volume":"22","author":"Erculj","year":"2012","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.gene.2015.01.010_bb0025","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/tpj.2011.22","article-title":"Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704","volume":"12","author":"Farrell","year":"2012","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.gene.2015.01.010_bb0030","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1158\/1078-0432.CCR-05-1969","article-title":"Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics","volume":"12","author":"Gilbert","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.gene.2015.01.010_bb0035","first-page":"6823","article-title":"Pharmacologically directed design of the dose rate and schedule of 2\u2032,2\u2032-difluorodeoxycytidine (Gemcitabine) administration in leukemia","volume":"50","author":"Grunewald","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/j.gene.2015.01.010_bb0040","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1365-2125.2007.03040.x","article-title":"Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate","volume":"65","author":"Jiang","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.gene.2015.01.010_bb0045","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00280-011-1670-4","article-title":"Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin\/gemcitabine","volume":"69","author":"Joerger","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.gene.2015.01.010_bb0050","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1002\/cncr.26562","article-title":"Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum\u2013gemcitabine chemotherapy: A prospective clinical study","volume":"118","author":"Joerger","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.gene.2015.01.010_bb0055","first-page":"1609","article-title":"Prediction of a side effect and efficacy of adjuvant chemotherapy with gemcitabine for post operative patient of pancreatic cancer by a genetic polymorphism analysis","volume":"59","author":"Kasuya","year":"2012","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.gene.2015.01.010_bb0060","doi-asserted-by":"crossref","first-page":"820","DOI":"10.7326\/0003-4819-127-9-199711010-00008","article-title":"Quantitative synthesis in systematic reviews","volume":"127","author":"Lau","year":"1997","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.gene.2015.01.010_bb0065","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.lungcan.2004.10.014","article-title":"Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes","volume":"47","author":"Le Chevalier","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.gene.2015.01.010_bb0070","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/FPC.0b013e32834dd7e2","article-title":"Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer","volume":"22","author":"Li","year":"2012","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.gene.2015.01.010_bb0075","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1097\/JTO.0b013e3182307e1f","article-title":"Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin\/gemcitabine-treated advanced non-small cell lung cancer patients","volume":"6","author":"Ludovini","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.gene.2015.01.010_bb0080","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gene.2015.01.010_bb0085","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1743-7563.2010.01354.x","article-title":"The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>C","volume":"7","author":"Metharom","year":"2011","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"10.1016\/j.gene.2015.01.010_bb0090","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.gene.2015.01.010_bb0095","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1158\/1078-0432.CCR-09-1555","article-title":"Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity","volume":"16","author":"Okazaki","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.gene.2015.01.010_bb0100","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ejca.2010.11.032","article-title":"Association of RRM1-37A>C polymorphism with clinical outcome in colorectal cancer patients treated with gemcitabine-based chemotherapy","volume":"47","author":"Rodriguez","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.gene.2015.01.010_bb0105","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.lungcan.2008.04.010","article-title":"Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients","volume":"63","author":"Soo","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.gene.2015.01.010_bb0110","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1200\/JCO.2006.06.8015","article-title":"Lung cancer in never smokers: a review","volume":"25","author":"Subramanian","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gene.2015.01.010_bb0115","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1200\/JCO.2006.06.7405","article-title":"Pharmacokinetics of gemcitabine in Japanese cancer patients: The impact of a cytidine deaminase polymorphism","volume":"25","author":"Sugiyama","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gene.2015.01.010_bb0120","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2165\/11532970-000000000-00000","article-title":"Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms","volume":"49","author":"Sugiyama","year":"2010","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.gene.2015.01.010_bb0125","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1002\/cncr.25282","article-title":"Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer","volume":"116","author":"Tanaka","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.gene.2015.01.010_bb0130","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.gene.2015.01.010_bb0135","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1158\/1078-0432.CCR-07-1364","article-title":"Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine\/cisplatin-treated advanced non-small cell lung cancer patients","volume":"14","author":"Tibaldi","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.gene.2015.01.010_bb0140","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/annonc\/mdr280","article-title":"Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-\/platinum-treated advanced non-small-cell lung cancer patients","volume":"23","author":"Tibaldi","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.gene.2015.01.010_bb0145","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1517\/14796694.1.1.7","article-title":"Role of gemcitabine in cancer therapy","volume":"1","author":"Toschi","year":"2005","journal-title":"Future Oncol."},{"key":"10.1016\/j.gene.2015.01.010_bb0150","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/nrc1233","article-title":"Cancer pharmacogenetics: polymorphisms, pathways and beyond","volume":"3","author":"Ulrich","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.gene.2015.01.010_bb0155","unstructured":"Wells, G., Shea, B., D., O.C., Peterson, J., Welch, V., Losos, M., Tugwell, P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, Last access on January 2015."},{"key":"10.1016\/j.gene.2015.01.010_bb0160","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/03602530902741828","article-title":"Clinical pharmacology and pharmacogenetics of gemcitabine","volume":"41","author":"Wong","year":"2009","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.gene.2015.01.010_bb0165","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.cca.2012.04.018","article-title":"High incidence of severe neutropenia after gemcitabine-based chemotherapy in Chinese cancer patients with CDA 79A>C mutation","volume":"413","author":"Xu","year":"2012","journal-title":"Clin. Chim. Acta"}],"container-title":["Gene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111915000268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111915000268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T14:02:49Z","timestamp":1566223369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378111915000268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S0378111915000268"],"URL":"https:\/\/doi.org\/10.1016\/j.gene.2015.01.010","relation":{},"ISSN":["0378-1119"],"issn-type":[{"value":"0378-1119","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Gene","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gene.2015.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}